The 35 most recent market catalysts affecting $TWST, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 15, 2026
Corporate Catalyst
Neutral
Impact 55
Wall Street Analysts Update Ratings and Price Targets for Twist Bioscience
On November 14, 2026, four prominent Wall Street analysts issued updated research notes on Twist Bioscience. All analysts maintained their 'buy' ratings, signaling continued confid…
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 65
Canaccord Genuity Cuts Twist Bioscience Price Target to $150
Canaccord Genuity, a well-known financial firm, has significantly reduced its price target for Twist Bioscience (TWST) from $205 to $150. This 26.8% reduction signals a more conser…
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Buy Rating on Twist Bioscience and Raises Price Target to $135
Baird analyst Catherine Ramsey Schulte has reaffirmed a 'Buy' rating on Twist Bioscience (TWST) and raised the price target from $115 to $135. This action signals increased confide…
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 75
Analysts Adjust Price Targets for Twist Bioscience
Guggenheim and BofA Securities have both lowered their price targets for Twist Bioscience (TWST) shares, with Guggenheim reducing its target from $212 to $150 and BofA from $205 to…
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 65
Guggenheim Lowers Price Target on Twist Bioscience
Guggenheim, a notable financial institution, has significantly reduced its price target for Twist Bioscience (TWST) from $212 to $150. This action signals a material shift in the f…
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 95
Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
Twist Bioscience has announced its financial results for the fourth quarter and full fiscal year 2026. This is a significant event for the company and its investors, as earnings re…
Nov 5, 2026
Corporate Catalyst
Bearish
Impact 75
Twist Bioscience Faces Negative Report from The Bear Cave and Hunterbrook
Twist Bioscience experienced a stock price drop after a negative report was published by The Bear Cave and Hunterbrook. This event is significant because negative research reports …
Nov 2, 2026
Corporate Catalyst
Bearish
Impact 55
Ark Invest Sells $7.3 Million in Twist Bioscience Shares
Ark Invest executed a sale of $7.3 million in Twist Bioscience (TWST) stock, which is part of a larger portfolio adjustment that also included reductions in semiconductor and healt…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 60
Twist Bioscience Launches Twist MRD Express for Cancer Research
Twist Bioscience announced the launch of Twist MRD Express, a custom panel solution for cancer research. This product is significant as it addresses the increasing need for persona…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 65
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205
Canaccord Genuity analyst Kyle Mikson maintained a 'Buy' rating on Twist Bioscience and substantially raised the price target from $120 to $205. This action indicates a significant…
Oct 8, 2026
Corporate Catalyst
Bearish
Impact 75
Twist Bioscience shares are trading lower after Jefferies initiated coverage on the stock with a Hold rating and announced a $150 price target.
The initiation of coverage by a prominent investment bank like Jefferies, especially with a 'Hold' rating and a specific price target, carries significant weight in the market. For…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 55
Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150
Jefferies analyst Matthew Stanton has initiated coverage on Twist Bioscience (TWST) with a 'Hold' rating and a price target of $150. This event is significant as new analyst covera…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215
Barclays analyst Luke Sergott maintained an 'Overweight' rating on Twist Bioscience (TWST) and substantially raised the price target from $112 to $215. This significant increase in…
Oct 6, 2026
Corporate Catalyst
Bearish
Impact 65
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK Invest is undertaking a notable rebalancing within its healthcare ETFs, particularly ARKK and ARKG. The most significant action is the continued and heavy selling…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 75
TWST stock has given up its prior gain. Twist Bioscience shares were trading higher after Guggenheim raised its price target on the stock from $107 to $212.
The headline presents a classic 'buy the rumor, sell the news' scenario, or at least a 'buy the upgrade, sell the immediate pop' situation. While a doubling of a price target from …
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience shares are trading higher after Guggenheim raised its price target on the stock from $107 to $212.
This headline indicates a strong positive catalyst for Twist Bioscience. A near-doubling of a price target by a reputable firm like Guggenheim suggests a re-evaluation of the compa…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 65
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Twist Bioscience and more than doubled the price target from $107 to $212. This significant upgrade indicates a stro…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience shares are trading higher after Leerink Partners maintained an Outperform rating on the stock and raised its price target from $160 to $190.
The maintained 'Outperform' rating and significant price target increase from a reputable firm like Leerink Partners serve as a strong positive catalyst for Twist Bioscience. This …
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190
Leerink Partners analyst Puneet Souda has maintained an 'Outperform' rating on Twist Bioscience and raised the price target from $160 to $190. This analyst action signals continued…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 85
Twist Bioscience shares are trading higher after the company announced an agreement with Lilly TuneLab to advance antibody drug discovery.
This headline represents a significant corporate catalyst for Twist Bioscience. The agreement with a major pharmaceutical company like Eli Lilly (via TuneLab) provides strong valid…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience Announces Agreement With Lilly TuneLab To Advance Antibody Drug Discovery
This collaboration is a significant positive for Twist Bioscience, validating their synthetic biology platform and potentially leading to future revenue streams and partnerships. F…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45
BWS Financial's initiation of coverage on Twist Bioscience with a 'Sell' rating and a $45 price target is a significant event for the company. Analyst ratings, especially new initi…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144
UBS analyst Doug Schenkel initiated coverage on Twist Bioscience (TWST) with a 'Neutral' rating and a $144 price target. This event is significant as it introduces a new institutio…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 85
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
Twist Bioscience (TWST) shares experienced a significant surge, reaching a 52-week high, after Anthropic named them an 'independent evaluator' in an AI-driven protein design campai…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 85
Twist Bioscience shares are trading higher after Anthropic named the company as an independent evaluator in a protein design campaign using its Claude Opus 4.8 and Mythos Preview AI models.
This headline represents a strong corporate catalyst for Twist Bioscience. Being selected by Anthropic, a prominent AI company, as an independent evaluator for a protein design cam…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience shares are trading higher after Piper Sandler maintained its Overweight rating on the stock and raised its price target from $85 to $115.
The headline indicates a significant positive catalyst for Twist Bioscience (TWST). Piper Sandler's maintained 'Overweight' rating and substantial price target increase from $85 to…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 75
Twist Bioscience Announces $250M Public Stock Offering
Twist Bioscience's $250M public stock offering is a significant corporate catalyst. While it provides crucial capital for R&D, manufacturing expansion, and potential M&A, it will l…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115
Baird analyst Catherine Ramsey maintained an 'Outperform' rating on Twist Bioscience and slightly increased the price target from $113 to $115. This action signals continued positi…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 85
Twist Bioscience Sees AI Drug Discovery Pipeline Expand
Twist Bioscience's fiscal Q3 2026 results show a mixed picture with a wider adjusted loss but significantly stronger sales than anticipated, beating both consensus and management g…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 75
Twist Bioscience Corporation shares are trading lower after the company reported mixed Q3 financial results.
The headline indicates a direct corporate catalyst impacting Twist Bioscience. 'Mixed' results often lead to volatility as investors digest both positive and negative aspects, but …
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience Q3 EPS $(0.56) Misses $(0.50) Estimate, Sales $118.376M Beat $114.490M Estimate
The headline indicates a classic 'good news, bad news' scenario for Twist Bioscience. While the sales beat demonstrates strong demand for their synthetic DNA and genomics products,…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Twist Bioscience Raises FY2026 Sales Guidance from $442.000M-$447.000M to $456.000M-$457.000M vs $446.103M Est
Twist Bioscience (TWST) has announced an upward revision to its FY2026 sales guidance, moving from $442M-$447M to $456M-$457M. This is a significant development as the new guidance…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 75
Twist Bioscience Sees Q4 Sales $123.000M-$124.000M vs $117.546M Est
Twist Bioscience (TWST) has pre-announced its Q4 sales guidance, projecting figures between $123.000 million and $124.000 million. This range is notably higher than the analyst con…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120
Canaccord Genuity analyst Kyle Mikson has maintained a 'Buy' rating on Twist Bioscience and raised the price target from $90 to $120. This analyst action signals increased confiden…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.